Partner with us
Our partnering areas of interest
In our vision of data-driven medicine, robust disease characterization through aggregated, multimodal data enables personalized care throughout an individual’s treatment journey. For instance, in oncology we aim to assess tumor evolution by combining tumor profiling at the molecular level with longitudinal follow-up using radiomic, pathology, laboratory, and clinical data.
Each institution within the SOPHiA GENETICS community gains knowledge and insights to improve their expertise in treating disease. Therefore, the aggregated insights from anonymized data across institutions create a collective intelligence on multiple disorders. This further supports confident, informed decision-making and can accelerate the discovery and improvement of targeted therapeutics.
To fully leverage this potential requires a decentralized approach enabling any permissioned user to produce and share data and derive insights through a secure cloud platform.
This approach can be applied across many disease areas. SOPHiA GENETICS has specific interest in oncology, rare disease, cardiology, neurology, and metabolism.
Why partner with us?
At SOPHiA GENETICS, we believe in the power of collaboration. We build long-term relationships for unique value, from deep expertise in genomic insight generation and multiple data modality analysis and interpretation to clinical trial matching and access to innovative technologies. Our partnerships focus on acceleration of clinical research and precision medicine discoveries.
Our Featured Partners
“The integration of genomics-based artificial intelligence into oncology workflow solutions would be a major breakthrough for integrated cancer medicine and for future clinical research, which increasingly depend on the ability to select those patients most likely to respond to new therapies,” said Jan Makela, President & CEO, Imaging at GE Healthcare. ”This collaboration [with SOPHiA GENETICS] represents another step in GE Healthcare’s vision of making precision health — more efficient and personalized care — a reality.”
Jan Makela, President & CEO
– GE Healthcare
“SOPHiA GENETICS is a leader in precision medicine,” said Keiji Kojima, Executive Vice President and Executive Officer, and General Manager of Smart Life Business Management Division of Hitachi, Ltd. “Hitachi is excited to start long term partnership with SOPHiA GENETICS to co-create innovative solutions for improving Quality of Life of patients by leveraging both companies’ data analytics and AI technologies.”
Keiji Kojima, Executive Vice President, Executive Officer, & General Manager of Smart Life Business Management Division
– Hitachi
This information is as of the date of the press announcement on March 25, 2021.
“These remarkable partners have displayed a deep commitment to building world-class solutions for customers — from cloud-to-edge — and represent some of the best and brightest our ecosystem has to offer,” said Rodney Clark, Corporate Vice President of Global Partner Solutions in Channel Sales and Channel Chief at Microsoft.
Rodney Clark, Corporate Vice President of Global Partner Solutions in Channel Sales & Channel Chief
– Microsoft
“Genomics research is enabling a shift from a broad-based one-size-fits-all approach to a personalized experience. Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA GENETICS robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA GENETICS to provide this new combined offering to clinical researchers around the world.”
Emily M. Leproust, Ph.D., CEO and Co-founder
– Twist Bioscience
Ready to discuss a potential partnering opportunity?
We would like to meet and discuss how we might collaborate and add value through partnership. Please let us know how to reach you by completing the form below or email us at [email protected]. In addition, let us know if we can connect at an upcoming event.